Volume Alert - ACHN 12.88 Achillion Pharmaceuticals $ACHN

New Post Public Reply Private Reply Replies (0) Message Board

Nov 12, 2014 at 12:04 PM

Volume Alert - ACHN 12.88 Achillion Pharmaceuticals $ACHN Hit a high today of 13.08 Closing the day 10:30 at 12.88 +0.40 +3.21% With a day low of 12.00 and a total volume of 2,379,091.

ACHN Recent Posts: http://investorshangout.com/Achillion-Pharmac...CHN-53213/

ACHN Achillion Pharmaceuticals Recent Headline News

Achillion Pharmaceuticals (ACHN) Stock Rises on Positive Hepatitis C Drug Results
at The Street - 6 mins ago
Shares of Achillion Pharmaceuticals (ACHN) continued to rise Wednesday after the company reported encouraging interim results from a Phase II study of its hepatitis C drug ACH-3102.
ACHN: 13.33 (+0.85)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 116.23 (-1.26), GILD: 106.77 (-1.24), ACHN: 13.33 (+0.85), DNDN: 0.17 (+0.02), AMGN: 162.31 (-0.11), ABBV: 63.84 (-0.01), REGN: 400.01 (+1.65)

This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 7:43AM CST
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 106.77 (-1.24), ACHN: 13.33 (+0.85), MRK: 59.29 (-0.08)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 83.15 (+2.28), OREX: 6.05 (+1.01), PCMI: 8.78 (-0.12), CYAN: 6.04 (-0.02), ACHN: 13.33 (+0.85), TGTX: 13.24 (+0.33), AGIO: 87.84 (+5.93), LIOX: 5.36 (-0.07), SAJA: 6.25 (+0.65), PLNR: 6.97 (+0.16)

Most active Nasdaq-traded stocks
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
FB: 73.92 (-0.69), ACHN: 13.33 (+0.85), DNDN: 0.17 (+0.02), CMCSK: 53.45 (+0.67), ARCP: 8.66 (unch), ZNGA: 2.81 (+0.06), MSFT: 48.79 (-0.08), INTC: 33.31 (unch), GRPN: 8.13 (+0.33), CMCSA: 53.59 (+0.63), AAPL: 110.88 (+1.18), CSCO: 25.04 (-0.11)

Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:10PM CST
Shares of Achillion Pharmaceuticals (ACHN) soared over 27% after the company reported encouraging interim results on ACH-3102.
JNJ: 108.87 (-0.04), GILD: 106.75 (-1.26), ACHN: 13.33 (+0.85), AMAG: 34.83 (-0.05)

Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 106.75 (-1.26), ACHN: 13.33 (+0.85), MRK: 59.29 (-0.08), ABBV: 63.84 (-0.01), BMY: 58.75 (+0.03)

Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST

JNJ: 108.87 (-0.04), GILD: 106.75 (-1.26), ACHN: 13.33 (+0.85), CNAT: 7.03 (-0.03), MRK: 59.29 (-0.08), RGLS: 20.02 (-0.45), ABBV: 63.84 (-0.01), BMY: 58.75 (+0.03), ENTA: 43.27 (+0.05)

AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST

JNJ: 108.87 (-0.04), GILD: 106.77 (-1.24), ACHN: 13.34 (+0.86), CNAT: 7.03 (-0.03), MRK: 59.29 (-0.08), RGLS: 20.02 (-0.45), ABBV: 63.84 (-0.01), BMY: 58.75 (+0.03), ENTA: 43.27 (+0.05)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST

JNJ: 108.87 (-0.04), GILD: 106.76 (-1.25), ACHN: 13.34 (+0.86), CNAT: 7.03 (-0.03), MRK: 59.29 (-0.08), LGND: 57.02 (+0.12), RGLS: 20.02 (-0.45), ABBV: 63.84 (-0.01), BMY: 58.75 (+0.03), ENTA: 43.27 (+0.05)

Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - Tue Nov 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ACHN, CLDX, KNDI, ILMN and AMD.
KNDI: 14.97 (-0.74), AMD: 2.69 (-0.04), ACHN: 13.34 (+0.86), CLDX: 14.65 (+0.19), ILMN: 187.86 (-0.18)

Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST

JNJ: 108.87 (-0.04), GILD: 106.76 (-1.25), ACHN: 13.34 (+0.86), CNAT: 7.03 (-0.03), LGND: 57.02 (+0.12), RGLS: 20.02 (-0.45), ABBV: 63.84 (-0.01), BMY: 58.75 (+0.03), ENTA: 43.27 (+0.05)

Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:44AM CST
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares surge a little over 27% on the day
HSKA: 15.96 (-0.18), ACHN: 13.34 (+0.86), ILMN: 187.86 (-0.18), AFFX: 9.49 (+0.07)

Achillion rises on new hepatitis C drug study
AP - Mon Nov 10, 1:17PM CST
NEW YORK (AP) — Shares of Achillion Pharmaceuticals climbed Monday after the company reported clinical trial results for one of its experimental hepatitis C drugs.
GILD: 106.76 (-1.25), ACHN: 13.34 (+0.86)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST

UCP: 11.47 (-0.23), JRJC: 7.38 (-0.11), NAVB: 1.02 (unch), SANW: 3.41 (-0.10), PLPM: 1.68 (-0.07), RYN: 26.31 (-0.42), INFU: 2.93 (unch), LIOX: 5.36 (-0.07), DY: 27.52 (-0.67), MTZ: 24.46 (-0.35), CGIX: 6.46 (-0.04), MUX: 1.33 (-0.01), OREX: 6.05 (+1.01), URRE: 2.47 (-0.04), ACHN: 13.34 (+0.86), REN: 2.57 (-0.13), MPO: 3.19 (+0.05), AKBA: 11.04 (+0.68), TRX: 1.05 (-0.01), PLNR: 6.97 (+0.16)

Achillion up on HCV data
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:30AM CST

ACHN: 13.34 (+0.86)

Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.84 (-0.07), GILD: 106.77 (-1.24), ACHN: 13.34 (+0.86), MRK: 59.29 (-0.08), ABBV: 63.84 (-0.01), BMY: 58.75 (+0.03)

Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 106.77 (-1.24), ACHN: 13.34 (+0.86), RGLS: 20.02 (-0.45), ABBV: 63.84 (-0.01)

Alexion Pharmaceuticals Inc. (ALXN) Stock Research Links

ALXN Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Ping An's Bold Green Moves Ahead of APEC 2026

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Spooky Dining at CARNE: A Halloween Hit in Oxnard

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Swanson Nexus Pro Launch: Boost for Dietitians

By Lucas Young Updated Oct 24, 2026 Category News Views 184

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Master Sommeliers and Italian Producers Clash on Wine Lists

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...